Identification of genome-wide cisplatin cross-linking sites with DNA base resolution

October 21, 2016, Wiley
Credit: Wiley

Cisplatin is one of the most widely used agents in cancer chemotherapy. Its mode of action is cross-linking of the DNA, which can kill cells. But which part of the genome is more affected, and which is less affected? A Chinese team of scientists have now set up a universal, genome-wide assay system to detect the specific cisplatin action sites, In the journal Angewandte Chemie the scientists introduce their system and report initial results, which support the notion that the mitochondrial genome is one of cisplatin's main targets.

Cancer cells are known to be extraordinarily active cells with their DNA replicating at a fast rate. Thus many anticancer drugs are designed to target DNA, and cisplatin is one most effective DNA-damaging agents. Its mode of action is relatively simple: The platinum atom binds to two neighboring DNA bases called guanines and cross-links them, thus widening the DNA duplex structure. If the DNA repair machinery cannot excise and refill all the damaged positions, the cell reprograms itself to induce apoptosis and cell death. Although the cisplatin action mechanism is quite clear, there has been only indirect evidence of the exact part of the genome preferentially targeted by cisplatin. In an interdisciplinary collaboration, Chengqi Yi from Peking University, Beijing, China and Chuan He from Peking University, University of Chicago and Howard Hughes Medical Institute, Chicago, USA, have developed a universal test system called "cisplatin-seq" to identify specifically the genomic parts preferentially attacked by cisplatin.

Key in their test system is the enrichment of cisplatin-affected sites by taking advantage of a specific DNA-binding protein, which was called HMGB1. A segment of this protein (its domain A) was used to enrich the fragments containing the cisplatin- modified DNA and subject them to high-throughput sequencing. The goal was to identify the exact bases where cisplatin had added. "Owing to the ability of cisplatin-DNA adducts to stall DNA synthesis, cisplatin cross-linking sites can be identified at base resolution through the genome," Yi, He, and their colleagues wrote. Or to put it differently, the sequencing stops exactly at the site where the cross-linking has occurred.

The big advantage of cisplatin-seq is the detection of cisplatin-DNA adducts genome-wide. Thus the scientists could verify the previous assumption that it is the mitochondrial DNA that is especially sensitive to cisplatin action. "Mitochondrial DNA, which is devoid of histone proteins or NER (one of the DNA repair systems), was found to be a major target of cisplatin," they said, adding: "...while for DNA in the nucleus of cancer cells, binding of proteins to DNA largely contributes to the accumulative pattern of cisplatin-DNA adducts." Further applications of cisplatin-seq could include, for example, the profiling of cisplatin-DNA adducts under different dosages of cisplatin treatment. It would be a highly interesting further step in cancer therapy and analytics.

Explore further: TP53, MDM2 alterations linked to cisplatin resistance in GCT

More information: Xiaoting Shu et al, Base-Resolution Analysis of Cisplatin-DNA Adducts at the Genome Scale, Angewandte Chemie International Edition (2016). DOI: 10.1002/anie.201607380

Related Stories

TP53, MDM2 alterations linked to cisplatin resistance in GCT

September 23, 2016

(HealthDay)—In germ cell tumors (GCTs), TP53 and MDM2 alterations correlate with cisplatin resistance and are associated with inferior outcome, according to a study published online Sept. 19 in the Journal of Clinical Oncology.

Fine tuning an old-school chemotherapy drug

May 5, 2014

First approved by the FDA in the 1970s, the chemotherapy drug cisplatin and its relative carboplatin remain mainstays of treatment for lung, head and neck, testicular and ovarian cancer. However, cisplatin's use is limited ...

Venous thromboembolism risk up with cisplatin-based chemo

November 15, 2012

(HealthDay)—Patients with advanced solid tumors receiving cisplatin-based chemotherapy regimens have a significantly higher risk of having a venous thromboembolic event (VTE) compared with those who do not receive a cisplatin-based ...

Recommended for you

Nanoscale Lamb wave-driven motors in nonliquid environments

March 19, 2019

Light driven movement is challenging in nonliquid environments as micro-sized objects can experience strong dry adhesion to contact surfaces and resist movement. In a recent study, Jinsheng Lu and co-workers at the College ...

OSIRIS-REx reveals asteroid Bennu has big surprises

March 19, 2019

A NASA spacecraft that will return a sample of a near-Earth asteroid named Bennu to Earth in 2023 made the first-ever close-up observations of particle plumes erupting from an asteroid's surface. Bennu also revealed itself ...

The powerful meteor that no one saw (except satellites)

March 19, 2019

At precisely 11:48 am on December 18, 2018, a large space rock heading straight for Earth at a speed of 19 miles per second exploded into a vast ball of fire as it entered the atmosphere, 15.9 miles above the Bering Sea.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.